Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 5/2024

01-03-2024 | Type 2 Diabetes | REVIEW

Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review

Authors: Reza Pishdad, Paul G. Auwaerter, Rita R. Kalyani

Published in: Current Diabetes Reports | Issue 5/2024

Login to get access

Abstract

Purpose of Review

The aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections.

Recent Findings

Individuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic agents, and studies suggest that they are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications with a patient-centric approach are the most recognized methods for preventing critical long-term complications including genitourinary manifestations of diabetes.

Summary

The available data regarding the association of SGLT-2 inhibitors with genitourinary infections is more comprehensive compared to that with UTIs. Further research is needed to better understand the mechanisms underlining the association between SGLT-2 inhibitors and genital infections and UTIs.
Literature
1.
Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16(Suppl1):S27-36.PubMedPubMedCentral
2.
Garg V, Bose A, Jindal J, Goyal A. Comparison of clinical presentation and risk factors in diabetic and non-diabetic females with urinary tract infection assessed as per the European Association of Urology Classification. J Clin Diagn Res. 2015;9(6):PC12-4.PubMedPubMedCentral
3.
Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677–84.PubMedCrossRef
4.
Fu AZ, Iglay K, Qiu Y, Engel S, Shankar R, Brodovicz K. Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes. J Diabetes Complicat. 2014;28(6):805–10.CrossRef
5.
Sewify M, Nair S, Warsame S, Murad M, Alhubail A, Behbehani K, et al. Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled glycemia in Kuwait. J Diabetes Res. 2016;2016:6573215.PubMedCrossRef
6.
Nichols GA, Brodovicz KG, Kimes TM, Déruaz-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complicat. 2017;31(11):1587–91.CrossRef
7.
Wilke T, Boettger B, Berg B, Groth A, Mueller S, Botteman M, et al. Epidemiology of urinary tract infections in type 2 diabetes mellitus patients: an analysis based on a large sample of 456,586 German T2DM patients. J Diabetes Complicat. 2015;29(8):1015–23.CrossRef
8.
Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complicat. 2012;26(6):513–6.CrossRef
9.
MeC R-M, Pascual-Pérez R, Orozco-Beltrán D, Pérez-Barba C, Pedrera-Carbonell V. Risk factors for the development and persistence of asymptomatic bacteriuria in patients with type 2 diabetes. Med Clin (Barc). 2005;125(16):606–10.
10.
Janifer J, Geethalakshmi S, Satyavani K, Viswanathan V. Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol. 2009;19(3):107–11.PubMedPubMedCentralCrossRef
11.
Goswami R, Bal CS, Tejaswi S, Punjabi GV, Kapil A, Kochupillai N. Prevalence of urinary tract infection and renal scars in patients with diabetes mellitus. Diabetes Res Clin Pract. 2001;53(3):181–6.PubMedCrossRef
12.
Tourret J, Bagnis CI, Denamur E. Urinary tract infections in diabetic patients. Rev Prat. 2014;64(7):980–3.PubMed
13.
Hammar N, Farahmand B, Gran M, Joelson S, Andersson SW. Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials. Pharmacoepidemiol Drug Saf. 2010;19(12):1287–92.PubMedCrossRef
14.
Boroumand MA, Sam L, Abbasi SH, Salarifar M, Kassaian E, Forghani S. Asymptomatic bacteriuria in type 2 Iranian diabetic women: a cross sectional study. BMC Womens Health. 2006;6:4.PubMedPubMedCentralCrossRef
15.
de Lastours V, Foxman B. Urinary tract infection in diabetes: epidemiologic considerations. Curr Infect Dis Rep. 2014;16(1):389.PubMedCrossRef
16.
Zhanel GG, Harding GK, Nicolle LE. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis. 1991;13(1):150–4.PubMedCrossRef
17.
Harwalkar A, Gupta S, Rao A, Srinivasa H. Prevalence of virulence factors and phylogenetic characterization of uropathogenic Escherichia coli causing urinary tract infection in patients with and without diabetes mellitus. Trans R Soc Trop Med Hyg. 2015;109(12):769–74.PubMed
18.
Lye WC, Chan RK, Lee EJ, Kumarasinghe G. Urinary tract infections in patients with diabetes mellitus. J Infect. 1992;24(2):169–74.PubMedCrossRef
19.
Bonadio M, Costarelli S, Morelli G, Tartaglia T. The influence of diabetes mellitus on the spectrum of uropathogens and the antimicrobial resistance in elderly adult patients with urinary tract infection. BMC Infect Dis. 2006;6:54.PubMedPubMedCentralCrossRef
20.
Chen HS, Su LT, Lin SZ, Sung FC, Ko MC, Li CY. Increased risk of urinary tract calculi among patients with diabetes mellitus–a population-based cohort study. Urology. 2012;79(1):86–92.PubMedCrossRef
21.
James R, Hijaz A. Lower urinary tract symptoms in women with diabetes mellitus: a current review. Curr Urol Rep. 2014;15(10):440.PubMedCrossRef
22.
Geerlings SE. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents. 2008;31(Suppl 1):S54–7.PubMedCrossRef
23.
Hoepelman IM. Urinary tract infection in patients with diabetes mellitus. Int J Antimicrob Agents. 1994;4(2):113–6.PubMedCrossRef
24.
Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents. 2003;22(Suppl 2):35–43.PubMedCrossRef
25.
Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129–36.PubMedPubMedCentral
26.
Chen SL, Jackson SL, Boyko EJ. Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models. J Urol. 2009;182(6 Suppl):S51–6.PubMed
27.
Geerlings SE, Meiland R, Hoepelman IM. Urinary tract infections in women with diabetes mellitus. Ned Tijdschr Geneeskd. 2001;145(38):1832–6.PubMed
28.
Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI, et al. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23(12):1737–41.PubMedCrossRef
29.
Al-Rubeaan KA, Moharram O, Al-Naqeb D, Hassan A, Rafiullah MR. Prevalence of urinary tract infection and risk factors among Saudi patients with diabetes. World J Urol. 2013;31(3):573–8.PubMedCrossRef
30.
Sanden AK, Johansen MB, Pedersen L, Lervang HH, Schønheyder HC, Thomsen RW. Change from oral antidiabetic therapy to insulin and risk of urinary tract infections in type 2 diabetic patients: a population-based prescription study. J Diabetes Complicat. 2010;24(6):375–81.CrossRef
31.
NjomnangSoh P, Vidal F, Huyghe E, Gourdy P, Halimi JM, Bouhanick B. Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab. 2016;42(1):16–24.CrossRef
32.
•• Benjamin T, Schumacher C. Characterization of risk factors for genitourinary infections with sodium-glucose cotransporter-2 inhibitors. Pharmacotherapy. 2020;40(10):1002–11.While certain factors like estimated glomerular filtration rate (eGFR) and a history of genitourinary infections increase the risk, the overall incidence of infections related to SGLT2 inhibitors might be lower than initially suggested.PubMedCrossRef
33.
•• Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine. 2021;41:101163.The observed impacts of SGLT-2 inhibition on essential safety and effectiveness outcomes remain consistent among various patient groups studied.PubMedPubMedCentralCrossRef
34.
Schneeberger C, Kazemier BM, Geerlings SE. Asymptomatic bacteriuria and urinary tract infections in special patient groups: women with diabetes mellitus and pregnant women. Curr Opin Infect Dis. 2014;27(1):108–14.PubMedCrossRef
35.
Aggarwal A, Wadhwa R, Kapoor D, Khanna R. High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among Indian patients with type 2 diabetes. Indian J Endocrinol Metab. 2019;23(1):9–13.PubMedPubMedCentralCrossRef
36.
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248–56.PubMedPubMedCentralCrossRef
37.
Rizzi M, Trevisan R. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. Nutr Metab Cardiovasc Dis. 2016;26(11):963–70.PubMedCrossRef
38.
•• Wiegley N, So PN. Sodium-glucose cotransporter 2 inhibitors and urinary tract infection: is there room for real concern? Kidney360. 2022;3(11):1991–3.This study serves as a pivotal resource providing reassurance to both patients and prescribers, thereby advocating for the broader and confident utilization of SGLT-2 I in clinical practice for enhanced kidney and heart protection.
39.
Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014;40(6 Suppl 1):S28-34.PubMedCrossRef
40.
Yang H, Choi E, Park E, Na E, Chung SY, Kim B, et al. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: a retrospective cohort study in Korea. Pharmacol Res Perspect. 2022;10(1):e00910.PubMedPubMedCentralCrossRef
41.
Liao HW, Wu YL, Sue YM, Lee M, Ovbiagele B. Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Endocrinol Diabetes Metab. 2019;2(1):e00050.PubMedCrossRef
42.
Liu D, Chen H, Song F, Ahmed MA, Wu H. Adverse drug events observed with the novel sodium/glucose co-transporter 2 inhibitor ipragliflozin for the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized studies. Adv Ther. 2020;37(10):4356–69.PubMedCrossRef
43.
Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503–14.PubMedCrossRef
44.
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27(5):473–8.CrossRef
45.
•• Zheng Z, He D, Chen J, Xie X, Lu Y, Wu B, et al. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023;43(4):209–25.This study encompasses a comprehensive examination of 42 RCTs involving 35,938 patients, revealing that dapagliflozin administration poses a higher UTI risk compared to both placebo and other active treatments, particularly emphasizing heightened risks with higher dosages of dapagliflozin.PubMedCrossRef
46.
•• Liew A, Lydia A, Matawaran BJ, Susantitaphong P, Tran HTB, Lim LL. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-an expert consensus statement. Nephrology (Carlton). 2023;28(8):415–24.This study critically addresses the discrepancy between the well-documented clinical benefits of SGLT-2 inhibitors and their notably low utilization rates, notably prevalent within low-resource settings. It emphasizes the contributing factors to this pattern, such as clinician unfamiliarity with the evolving organ-protective role attributed to these agents, apprehensions concerning potential adverse effects, and uncertainties regarding the safety profiles specifically in elderly populations.PubMedCrossRef
47.
Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023;4(4):e143–54.PubMedCrossRef
48.
Boyko EJ, Fihn SD, Scholes D, Chen CL, Normand EH, Yarbro P. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care. 2002;25(10):1778–83.PubMedCrossRef
49.
Tandogdu Z, Cai T, Koves B, Wagenlehner F, Bjerklund-Johansen TE. Urinary tract infections in immunocompromised patients with diabetes, chronic kidney disease, and kidney transplant. Eur Urol Focus. 2016;2(4):394–9.PubMedCrossRef
50.
Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–54.PubMedCrossRef
51.
52.
Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34(1):230–5.PubMedCrossRef
53.
Meiland R, Geerlings SE, Stolk RP, Netten PM, Schneeberger PM, Hoepelman AI. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med. 2006;166(20):2222–7.PubMedCrossRef
54.
Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet JT, Schneeberger PM, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med. 2001;161(11):1421–7.PubMedCrossRef
55.
Harding GK, Zhanel GG, Nicolle LE, Cheang M. Group MDUTIS. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347(20):1576–83.PubMedCrossRef
56.
Ooi ST, Frazee LA, Gardner WG. Management of asymptomatic bacteriuria in patients with diabetes mellitus. Ann Pharmacother. 2004;38(3):490–3.PubMedCrossRef
57.
Cai T, Koves B, Johansen TE. Asymptomatic bacteriuria, to screen or not to screen - and when to treat? Curr Opin Urol. 2017;27(2):107–11.PubMedCrossRef
58.
Trautner BW. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol. 2011;9(2):85–93.PubMedCrossRef
59.
Schneeberger C, Erwich JJHM, van den Heuvel ER, Mol BWJ, Ott A, Geerlings SE. Asymptomatic bacteriuria and urinary tract infection in pregnant women with and without diabetes: Cohort study. Eur J Obstet Gynecol Reprod Biol. 2018;222:176–81.PubMedCrossRef
60.
Lerman-Garber I, Calva-Mercado JJ, Martínez-Sibaja C, del Castillo CF, Sánchez-Javier RM, Lara E, et al. Leukocyturia in women with diabetes and its clinical implications. Arch Med Res. 2000;31(2):210–5.PubMedCrossRef
61.
Søraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae–a case-control study in a low prevalence country. PLoS One. 2013;8(7):e69581.PubMedPubMedCentralCrossRef
62.
Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028–37.PubMedCrossRef
63.
García-Tello A, Gimbernat H, Redondo C, Meilán E, Arana DM, Cacho J, et al. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram. Scand J Urol. 2018;52(1):70–5.PubMedCrossRef
64.
Vinken JEM, Mol HE, Verheij TJM, van Delft S, Kolader M, Ekkelenkamp MB, et al. Antimicrobial resistance in women with urinary tract infection in primary care: no relation with type 2 diabetes mellitus. Prim Care Diabetes. 2018;12(1):80–6.PubMedCrossRef
65.
Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113(Suppl 1A):80S-S84.PubMedCrossRef
66.
DeYoung GR, Ashmead S. Screening for and treating asymptomiatic bacteriuria not useful in women with diabetes. J Fam Pract. 2003;52(2):98–9.PubMed
67.
ZalmanoviciTrestioreanu A, Lador A, Sauerbrun-Cutler MT, Leibovici L. Antibiotics for asymptomatic bacteriuria. Cochrane Database Syst Rev. 2015;4(4):CD009534.
68.
Grigoryan L, Zoorob R, Wang H, Horsfield M, Gupta K, Trautner BW. Less workup, longer treatment, but no clinical benefit observed in women with diabetes and acute cystitis. Diabetes Res Clin Pract. 2017;129:197–202.PubMedCrossRef
69.
Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1995;9(1):25–51.PubMedCrossRef
70.
Wan YL, Lee TY, Bullard MJ, Tsai CC. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology. 1996;198(2):433–8.PubMedCrossRef
71.
Grupper M, Kravtsov A, Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine (Baltimore). 2007;86(1):47–53.PubMedCrossRef
72.
Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160(6):797–805.PubMedCrossRef
73.
Amano M, Shimizu T. Emphysematous cystitis: a review of the literature. Intern Med. 2014;53(2):79–82.PubMedCrossRef
74.
75.
76.
Vollans SR, Sehjal R, Forster JA, Rogawski KM. Emphysematous pyelonephritis in type II diabetes: a case report of an undiagnosed ureteric colic. Cases J. 2008;1(1):192.PubMedPubMedCentralCrossRef
77.
Park BS, Lee SJ, Kim YW, Huh JS, Kim JI, Chang SG. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol. 2006;40(4):332–8.PubMedCrossRef
78.
Chiu PF, Huang CH, Liou HH, Wu CL, Wang SC, Chang CC. Long-term renal outcomes of episodic urinary tract infection in diabetic patients. J Diabetes Complicat. 2013;27(1):41–3.CrossRef
79.
Gandhi J, Dagur G, Warren K, Smith NL, Khan SA. Genitourinary complications of diabetes mellitus: an overview of pathogenesis, evaluation, and management. Curr Diabetes Rev. 2017;13(5):498–518.PubMedCrossRef
Metadata
Title
Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review
Authors
Reza Pishdad
Paul G. Auwaerter
Rita R. Kalyani
Publication date
01-03-2024
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits